Liposomes for HIV prophylaxis
There are approximately 33.4 million adults living with HIV worldwide of which an estimated 15.7 million are women. Although there has been enormous progress in the therapy of HIV/AIDS, treatment is not curative. Prevention is therefore of paramount importance, but vaccine-based and microbicidal app...
| Main Authors: | , , , , , , , , , |
|---|---|
| Other Authors: | |
| Format: | Article |
| Language: | English |
| Published: |
Elsevier BV
2021
|
| Online Access: | https://hdl.handle.net/1721.1/134469 |
| _version_ | 1826200771878715392 |
|---|---|
| author | Malavia, Nikita K Zurakowski, David Schroeder, Avi Princiotto, Amy M Laury, Anna R Barash, Hila E Sodroski, Joseph Langer, Robert Madani, Navid Kohane, Daniel S |
| author2 | Massachusetts Institute of Technology. Department of Chemical Engineering |
| author_facet | Massachusetts Institute of Technology. Department of Chemical Engineering Malavia, Nikita K Zurakowski, David Schroeder, Avi Princiotto, Amy M Laury, Anna R Barash, Hila E Sodroski, Joseph Langer, Robert Madani, Navid Kohane, Daniel S |
| author_sort | Malavia, Nikita K |
| collection | MIT |
| description | There are approximately 33.4 million adults living with HIV worldwide of which an estimated 15.7 million are women. Although there has been enormous progress in the therapy of HIV/AIDS, treatment is not curative. Prevention is therefore of paramount importance, but vaccine-based and microbicidal approaches are still in their infancy. Since women acquire the virus largely through sexual intercourse, we developed liposomal systems potentially suitable for intra-vaginal use to prevent HIV-1 infection. We formulated liposomes from a range of naturally-occurring and synthetic lipids with varying physicochemical properties, and tested their ability to inhibit infection of transformed cells that express receptors specific to the virus. We identified formulations with the most favorable balance between decreasing HIV infection and causing cytotoxicity (i.e. therapeutic index). The therapeutic index improved with increasing cardiolipin content, and degree of unsaturation. Tissue reaction to these formulations was benign after intra-vaginal instillation in an in vivo female mouse model. These results support the potential use of cardiolipin-based liposomes enriched with synthetic lipids as microbicides for the prevention of HIV infection in women. © 2011 Elsevier Ltd. |
| first_indexed | 2024-09-23T11:41:13Z |
| format | Article |
| id | mit-1721.1/134469 |
| institution | Massachusetts Institute of Technology |
| language | English |
| last_indexed | 2024-09-23T11:41:13Z |
| publishDate | 2021 |
| publisher | Elsevier BV |
| record_format | dspace |
| spelling | mit-1721.1/1344692023-02-24T19:03:13Z Liposomes for HIV prophylaxis Malavia, Nikita K Zurakowski, David Schroeder, Avi Princiotto, Amy M Laury, Anna R Barash, Hila E Sodroski, Joseph Langer, Robert Madani, Navid Kohane, Daniel S Massachusetts Institute of Technology. Department of Chemical Engineering There are approximately 33.4 million adults living with HIV worldwide of which an estimated 15.7 million are women. Although there has been enormous progress in the therapy of HIV/AIDS, treatment is not curative. Prevention is therefore of paramount importance, but vaccine-based and microbicidal approaches are still in their infancy. Since women acquire the virus largely through sexual intercourse, we developed liposomal systems potentially suitable for intra-vaginal use to prevent HIV-1 infection. We formulated liposomes from a range of naturally-occurring and synthetic lipids with varying physicochemical properties, and tested their ability to inhibit infection of transformed cells that express receptors specific to the virus. We identified formulations with the most favorable balance between decreasing HIV infection and causing cytotoxicity (i.e. therapeutic index). The therapeutic index improved with increasing cardiolipin content, and degree of unsaturation. Tissue reaction to these formulations was benign after intra-vaginal instillation in an in vivo female mouse model. These results support the potential use of cardiolipin-based liposomes enriched with synthetic lipids as microbicides for the prevention of HIV infection in women. © 2011 Elsevier Ltd. 2021-10-27T20:05:08Z 2021-10-27T20:05:08Z 2011 2019-09-04T17:07:53Z Article http://purl.org/eprint/type/JournalArticle https://hdl.handle.net/1721.1/134469 Malavia, N. K., et al. "Liposomes for Hiv Prophylaxis." Biomaterials (2011). en 10.1016/j.biomaterials.2011.07.068 Biomaterials Creative Commons Attribution-NonCommercial-NoDerivs License http://creativecommons.org/licenses/by-nc-nd/4.0/ application/pdf Elsevier BV PMC |
| spellingShingle | Malavia, Nikita K Zurakowski, David Schroeder, Avi Princiotto, Amy M Laury, Anna R Barash, Hila E Sodroski, Joseph Langer, Robert Madani, Navid Kohane, Daniel S Liposomes for HIV prophylaxis |
| title | Liposomes for HIV prophylaxis |
| title_full | Liposomes for HIV prophylaxis |
| title_fullStr | Liposomes for HIV prophylaxis |
| title_full_unstemmed | Liposomes for HIV prophylaxis |
| title_short | Liposomes for HIV prophylaxis |
| title_sort | liposomes for hiv prophylaxis |
| url | https://hdl.handle.net/1721.1/134469 |
| work_keys_str_mv | AT malavianikitak liposomesforhivprophylaxis AT zurakowskidavid liposomesforhivprophylaxis AT schroederavi liposomesforhivprophylaxis AT princiottoamym liposomesforhivprophylaxis AT lauryannar liposomesforhivprophylaxis AT barashhilae liposomesforhivprophylaxis AT sodroskijoseph liposomesforhivprophylaxis AT langerrobert liposomesforhivprophylaxis AT madaninavid liposomesforhivprophylaxis AT kohanedaniels liposomesforhivprophylaxis |